potassium diisopropylamide | 67459-71-6

• 分子结构分类: 有机化合物 - 有机盐 - 有机金属盐
• 英文名称: potassium diisopropylamide
• 英文别名: KDA；potassium;di(propan-2-yl)azanide
• CAS: 67459-71-6
• 化学式: C₆H₁₄N*K
• 分子量: 139.282
• InChiKey: ZMJJCODMIXQWCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.82
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  potassium diisopropylamide 、 Tris(trifluormethylseleno)methan 在 碘 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 生成 N,N-Diisopropyl-selenocarbamoylfluorid
  参考文献：
  名称：

  Darstellung und thermolyse von hexakis(perfluororganylthio/seleno)ethanen

  摘要：

  DOI：

  10.1016/s0040-4020(01)91334-1
• 作为产物：
  描述：

  二异丙胺 在 正丁基锂 、 potassium tert-butylate 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.17h， 生成 potassium diisopropylamide
  参考文献：
  名称：

  Darstellung und thermolyse von hexakis(perfluororganylthio/seleno)ethanen

  摘要：

  DOI：

  10.1016/s0040-4020(01)91334-1
• 作为试剂：
  描述：

  丙酮二甲腙 在 正丁基锂 、 potassium diisopropylamide 作用下， 反应 2.5h， 生成 N-[2,10-bis(trimethylsilyloxy)undecan-6-ylideneamino]-N-methylmethanamine
  参考文献：
  名称：

  Synthesis of Spiroacetal Pheromones via Metalated Hydrazones

  摘要：

  通过合适的亲电试剂与金属化丙酮二甲基脲的α,α′-烷基化反应，随后进行酸催化的断裂和环化闭合，描述了简单烷基取代螺缩醛的合成方法。

  DOI：

  10.1055/s-1990-27080

文献信息

• Bestimmung der ionenpaar-basizitǎt von lithium- und kaliumamiden
  作者：Hubertus Ahlbrecht、Gunther Scheneider

  DOI：10.1016/s0040-4020(01)82054-8

  日期：1986.1

  Ion pair basicities of lithio and potassio salts of some secondary amines were determined by equilibration with benzyl compounds. With these bases it is possible to span a range of about 19 pK-units from pK = 27 up to 46. The structural dependence of thermodynamic as well as kinetic basicity is discussed. Some new effective amide bases for preparative purposes are recommended. For the first time the

  通过与苄基化合物平衡来确定某些仲胺的硫代和钾代盐的离子对碱性。有了这些基础，就有可能跨越从pK = 27到46的约19 pK单位范围。讨论了热力学以及动力学基础的结构依赖性。推荐用于制备目的的一些新的有效酰胺碱。甲苯的pK值首次通过直接平衡确定。在四氢呋喃中为40.7。
• [EN] PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIDINE EN TANT QUE BLOQUANTS DE TTX-S
  申请人：RAQUALIA PHARMA INC

  公开号：WO2014068988A1

  公开（公告）日：2014-05-08

  The present invention relates to pyrazolopyridine derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及吡唑并吡啶衍生物，这些衍生物具有阻断TTX-S型电压门控钠通道的活性，并且在治疗或预防涉及电压门控钠通道的疾病和障碍中是有用的。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病中的用途。
• METHOD FOR MANUFACTURING PHOSPHONOCROTONIC ACID DERIVATIVE
  申请人：Ina Shinji

  公开号：US20140051876A1

  公开（公告）日：2014-02-20

  Provided is a method of manufacturing a high quality phosphonocrotonic acid derivative. The present invention is a method of manufacturing a compound represented by the following Formula (3) by reacting a compound represented by the following Formula (1) with a compound represented by the following Formula (2), which comprises a treatment process using an acid or base. [in the formula, R 1 represents a C 1-6 linear or branched alkyl group that may be substituted by a C 6-10 aryl group, a C 2-6 linear or branched alkenyl group that may be substituted by a C 6-10 aryl group, a C 2-6 linear or branched alkynyl group that may be substituted by a C 6-10 aryl group, or a C 6-10 aryl group, R 2 represents a hydrogen atom, or a C 1-6 linear or branched alkyl group that may be substituted by a C 6-10 aryl group, R 3 represents a C 1-6 linear or branched alkyl group, a C 6-10 aryl group, or a halogen atom, and X represents a halogen atom, and multiple R 1 s may be the same or different].

  提供了一种制造高质量磷酰肟酸衍生物的方法。本发明是一种通过用表示以下公式（1）的化合物与表示以下公式（2）的化合物反应，制造表示以下公式（3）的化合物的方法，该方法包括使用酸或碱的处理过程。 [在公式中，R1表示可以由C6-10芳基取代的C1-6直链或支链烷基，可以由C6-10芳基取代的C2-6直链或支链烯基，可以由C6-10芳基取代的C2-6直链或支链炔基，或C6-10芳基；R2表示氢原子或可以由C6-10芳基取代的C1-6直链或支链烷基；R3表示C1-6直链或支链烷基，C6-10芳基或卤素原子；X表示卤素原子，多个R1可以是相同的或不同的]。
• MONOMER, POLYMER, RESIST COMPOSITION, AND PATTERNING PROCESS
  申请人：SHIN-ETSU CHEMICAL CO., LTD.

  公开号：US20150322027A1

  公开（公告）日：2015-11-12

  A monomer (1) is prepared by reacting a compound (9) with a base or metal to form a metal enolate reagent, and reacting the metal enolate reagent with an acyloxyketone compound (8). A polymer derived from the monomer is used as base resin to formulate a resist composition, which is shelf stable and displays a high dissolution contrast, controlled acid diffusion and low roughness in forming positive pattern via alkaline development and in forming negative pattern via organic solvent development.

  一种单体（1）是通过将一种化合物（9）与碱或金属反应形成金属烯醇盐试剂，然后将金属烯醇盐试剂与一种酰氧基酮化合物（8）反应而制备的。由该单体派生出的聚合物用作基础树脂，以配制一种光刻胶组合物，该组合物在常温下稳定，显示出高溶解对比度、控制的酸性扩散和在碱性显影形成正图案以及有机溶剂显影形成负图案时低粗糙度。
• Oxyindole derivatives
  申请人：Uchida Chikara

  公开号：US20060194842A1

  公开（公告）日：2006-08-31

  This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: A, R 1 , R 2 , R 3 , R 4 and R 5 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT 4 agonistic activity such as, but not limited to, as gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageal disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes or apnea syndrome.

  这项发明涉及以下式（I）的化合物： 或其药学上可接受的盐，其中： A，R1，R2，R3，R4和R5分别如本文所述或药学上可接受的盐，以及含有这种化合物的组合物和利用这种化合物治疗由5-HT 4 激动活性介导的疾病的用途，例如但不限于胃食管反流病、胃肠疾病、胃动力障碍、非溃疡性消化不良、功能性消化不良、肠易激综合征（IBS）、便秘、消化不良、食管炎、胃食管疾病、恶心、中枢神经系统疾病、阿尔茨海默病、认知障碍、呕吐、偏头痛、神经系统疾病、疼痛、心血管疾病、心力衰竭、心律失常、糖尿病或呼吸暂停综合征。